Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 46-54 , March 2009

In vivo studies of polyacrylate nanoparticle emulsions for topical and systemic applications

Received 18 February 2008 ,Accepted 8 July 2008.

References 

  1. Zafeiris S. Antibiotics: A shot in the arm. Nature. 2004;431:892–893
  2. Chang FY, Peacock JE, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine. 2003;82:333–337
  3. Kugelberg E, Norstrom T, Petersen TK, Duvold T, Andersson DI, Hughes D. Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2005;49:3435–3451
  4. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol. 2001;55:77–104
  5. Goto Y, Hiramatsu K, Nasu M. Improved efficacy with non-simultaneous administration of netilmicin and minocycline against methicillin–resistant Staphylococcus aureus in in vitro and in vivo models. Int J Antimicrob Agents. 1999;11:39–46
  6. Norrby SN, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 2005;5:115–119
  7. Turos E, Shim JY, Wang Y, Greenhalgh K, Reddy GSK, Dickey S, et al. Antibiotic-conjugated polyacrylate nanoparticles: new opportunities for development of anti-MRSA agents. Bioorg Med Chem Lett. 2007;17:53–56
  8. Walsh C. Where will new antibiotics come from?. Nat Rev Microbiol. 2003;1:65–70
  9. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–1322
  10. Guignard B, Entenza JM, Moreillon P. β-lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol. 2005;5:479–489
  11. Cleary JD. Amphotericin B formulated in a liquid emulsion. Ann Pharmacother. 1996;30:409–412
  12. Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Bugelski P. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis. 1988;158:1065–1070
  13. Lamb KA, Washington C, Davis SS, Denyer SP. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers. J Pharm Pharmacol. 1991;43:522–524
  14. Lance MR, Washington C, Davis SS. Structure and toxicity of amphotericin B/triglyceride emulsion formulations. J Antimicrob Chemother. 1995;36:119–128
  15. Souza LC, Maranhão RC, Schreier S, Campa A. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J Antimicrob Chemother. 1993;32:123–132
  16. Sorkine P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med. 1996;24:1311–1315
  17. Washington C, Lance M, Davis SS. Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother. 1993;31:806–808
  18. Yarkoni E, Rapp HJ. Toxicity of emulsified trehalose-6,6′-dimycolate (cord factor) in mice depends on size distribution of mineral oil droplets. Infect Immun. 1978;20:856–860
  19. De TK, Bergey EJ, Chung SJ, Rodman DJ, Bharali DJ, Prasad PN. Polycarboxylic acid nanoparticles for ophthalmic drug delivery: an ex vivo evaluation with human cornea. J Microencapsul. 2004;21:841–855
  20. Gu H, Ho PL, Tong E, Wang L, Xu B. Presenting vancomycin on nanoparticles to enhance antimicrobial activity. Nano Lett. 2003;3:1261–1263
  21. Hussain F, Hojjati M. Polymer-matrix nanocomposites, processing, manufacturing, and application: an overview. [review] J Compos Mater. 2006;40:1511–1565
  22. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, et al. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16:2346–2353
  23. Ne A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311:622–627
  24. Renjis T, Tom V, Suryanarayanan P, Reddy G, Baskaran S, Pradeep T. Ciprofloxacin-protected gold nanoparticles. Langmuir. 2004;20:1909–1914
  25. Zheng F, Shi XW, Yang GF, Gong LL, Yuan HY, Cui YJ, et al. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: Results of an in vitro and in vivo study. Life Sci. 2007;80:388–396
  26. Cerrada ML, de la Fuente JL, Fernandez-Garcia M, Madruga EL. Viscoelastic and mechanical properties of poly(butyl acrylate-styrene) copolymers. Polymer. 2001;42:4647–4655
  27. Hicks R, Satti AK, Leach GDH, Naylor IL. Characterization of toxicity involving hemorrhage and cardiovascular failure, caused by parenteral administration of a soluble polyacrylate in the rat. J Appl Toxicol. 1989;9:191–198
  28. Junginger HE, Verhoef JC. Macromolecules as safe penetration enhancers for hydrophilic drugs-a fiction?. Pharm Sci Technol Today. 1998;1:370–376
  29. McGrath JJ, Purkiss L, Eberle M, McGrath WR. Long-term effects of a cross-linked polyacrylate superabsorbent in the hamster. J Appl Toxicol. 1994;15:69–73
  30. Mcgrath JJ, Purkiss L, Christian M, Proctor NH, McGrath WR. Teratology study of a cross-linked polyacrylate superabsorbent polymer. J Am Coll Toxicol. 1993;12:127–137
  31. Nolen GA, Monroe A, Hassall CD, Iavicoli J, Jamieson RA, Daston GP. Studies of the developmental toxicity of polycarboxylate dispersing agents. Drug Chem Toxicol. 1989;12:95–110
  32. Peters WJ, Jackson RW, Smith DC. Studies of the stability and toxicity of zinc polyacrylate (polycarboxylate) cements (PAZ). J Biomed Mater Res. 1974;8:53–60
  33. Peters WJ, Jackson RW, Iwano K, Smith DC. Biological response to zinc polyacrylate cement. Clin Orthop Relat Res. 1972;88:228–233
  34. Reich A, Kaplan A, Gisler R. Thermosetting polyacrylate powder coating compositions. European Patent Application. 1996;
  35. Tarasov VN, Boldasov VK. Bactericidal and antitoxic effects of synthetic polymers (review). Voen Med Zh. 1967;9:34–40
  36. Benita S. Prevention of topical and ocular oxidative stress by positively charged submicron emulsion. Biomed Pharmacother. 1999;53:193–206
  37. Deegan RJ. Propofol: a review of the pharmacology and applications of an intravenous anesthetic agent. Am J Med Sci. 1992;304:45–49
  38. Doenicke AW, Roizen MF, Rau J, Kellermann W, Babl J. Reducing pain during propofol injection: the role of the solvent. Anesth Analg. 1996;82:472–474
  39. Levy MY, Benita S. Design and characterization of submicronized o/w emulsion of diazepam for parenteral use. Int J Pharm. 1989;54:103–112
  40. Mizushima Y. Lipid microspheres (lipid emulsions) as a drug carrier—an overview. Adv Drug Deliv Rev. 1996;20:113–115
  41. van Dardel O, Mebius D, Svensson B. Fat emulsion as a vehicle for diazepam: a study of 9,492 patients. Br J Anaesth. 1981;55:41–47
  42. Turos E, Reddy GSK, Greenhalgh K, Ramaraju P, Abeylath SC, Jang S, et al. Penicillin-bound polyacrylate nanoparticles: restoring the activity of β-lactam antibiotics against MRSA. Bioorg Med Chem Lett. 2007;17:3468–3472
  43. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C Linezolid CSSTI study group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260–2266
  44. Tsuji M, Takema M, Miwa H, Shimada J, Kuwahara S. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob Agents Chemother. 2003;47:2507–2512
  45. Garay-Jimenez JC, Young A, Gergeres D, Greenhalgh K, Turos E. Methods for purifying and detoxifying sodium dodecyl sulfate–stabilized polyacrylate nanoparticles. Nanomedicine. 2008;4:1–8

 The authors would like to thank the US Army Medical Research Institute for Infectious Diseases for assistance with the ELISA experiments and the staff at the USF College of Medicine vivarium for their help with the animal experiments.

 All work presented in the manuscript was funded by a single National Science Foundation STTR grant (NSF 0419903) under a joint venture with Nanopharma Technologies, Inc. and the University of South Florida (USF). The technology described in this article is covered under a provisional patent obtained by E.T. through the USF Patents and Licensing Office (USF 03A018PR) and the International Patent Application (International Publication Number PCT WO 03A018PRCWO) are now licensed by Nanopharma Technologies, Inc.

PII: S1549-9634(08)00119-6

doi: 10.1016/j.nano.2008.07.004

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 46-54 , March 2009

Article Tools

* Image Usage & Resolution